Roughly one year after Eli Lilly and Bristol-Myers Squibb resolved their dispute over rights to the Erbitux follow-on necitumumab, the two pharmas co-developing the antibody got the bad news that it was increasing the risk of blood clots in one of two pivotal Phase III trials. Lilly and Bristol announced Feb. 2 that they have stopped enrolling patients for the INSPIRE trial in non-squamous, non-small cell lung cancer. In January 2010, the two companies ended a fight over which firm controlled development...